Business context and reporting period
This is OncoCyte Corporation’s Form 10-K for the fiscal year ended December 31, 2020, filed March 19, 2021. The request metadata names Insight Molecular Diagnostics Inc., but the filing is for OncoCyte Corporation (Nasdaq ticker: OCX). OncoCyte develops and commercializes molecular diagnostic tests, primarily for cancer. Its first clinical test, DetermaRx, helps stratify recurrence risk in early-stage non-small cell lung cancer; it also operates a pharmaceutical services business acquired with Insight Genetics in January 2020.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $1.216 million | None |
| Cost of revenue | $1.855 million | None |
| Gross loss / margin | $(0.639) million / approximately -52.5% | Not applicable |
| Research and development | $9.800 million | $6.794 million |
| General and administrative | $16.788 million | $13.281 million |
| Sales and marketing | $6.494 million | $2.164 million |
| Operating loss | $(29.711) million | $(22.239) million |
| Net loss | $(29.932) million | $(22.426) million |
| Basic and diluted loss per share | $(0.46) | $(0.44) |
| Cash used in operating activities | $26.0 million | $19.7 million |
- 2020 revenue comprised 45% DetermaRx and 55% Pharma Services. Medicare accounted for 40% of consolidated revenue; two Pharma Services customers accounted for 23% and 12%.
- Cash and cash equivalents were $7.143 million at year-end, down from $22.072 million. Marketable equity securities were valued at $0.675 million. Current assets were $9.226 million versus current liabilities of $8.996 million.
- Year-end loan payable totaled approximately $3.898 million, comprising current and noncurrent balances. Lease liabilities totaled approximately $4.734 million. The bank loan is secured by substantially all assets other than intellectual property.
- Financing activities provided $22.8 million in 2020; investing activities used $11.7 million. The company reported no off-balance-sheet arrangements.
- After year-end, OncoCyte reported raising $69.6 million in January and February 2021 equity transactions. It used $10 million of the proceeds to complete the Razor acquisition in February.
Material changes versus the prior comparable period
- Revenue began in 2020 with the DetermaRx launch and Insight Pharma Services acquisition; 2019 had no revenue. The comparison is affected by the acquisition and the company’s transition from development to commercialization.
- Operating expenses increased: R&D rose 44%, G&A 26%, and sales and marketing 200%, reflecting development, staffing, sales launch, and laboratory build-out. Cost of revenue was newly incurred.
- Net loss widened by approximately $7.5 million and operating cash use increased by approximately $6.3 million.
- A $4.010 million noncash gain from remeasurement of Insight contingent consideration reduced the reported 2020 operating loss; the liability was $7.120 million at year-end.
- OncoCyte discontinued DetermaDx development in the second quarter after a validation study failed to meet predetermined endpoints, recording a $0.422 million noncash impairment charge.
Outlook, commentary, risks and unusual items
- Management expected available cash, cash equivalents, and marketable securities to fund current operations for at least twelve months from the financial statement issuance date, taking account of subsequent financing. The company also stated it would need additional capital until revenues cover operating costs.
- Management planned continued DetermaRx commercialization and clinical studies, development of DetermaIO and other pipeline tests, and completion of the Irvine laboratory in 2021. It anticipated possible DetermaIO clinical-market launch in late Q3 or early Q4 2021, conditional on supporting data and other factors; DetermaIO was then offered for research and pharma studies, not routine clinical use.
- The proposed Chronix merger was pending at filing, subject to closing conditions. Planned consideration included $2.675 million cash for certain liabilities, 295,000 shares, assumption of up to $5.575 million of additional liabilities, and potential milestone and earnout payments. The filing anticipated an April 2021 closing if conditions were met.
- COVID-19 constrained in-person physician outreach, delayed some lung cancer surgeries and pharmaceutical trials, and made demand and revenue forecasts uncertain. Pharma Services revenue fell sequentially in Q4 as customer projects were delayed into the first half of 2021.
- Key risks include continuing losses and financing needs; potential shareholder dilution; dependence on a small number of tests and customers; uncertain clinical validation, physician adoption, and payer coverage; reimbursement and regulatory changes for laboratory-developed tests; intellectual property and licensing exposure; and integration and liability risks from acquisitions.
- The $1.141 million Paycheck Protection Program loan forgiveness application was pending; forgiveness was not assured. A $1.1 million severance accrual followed a partial reduction in force and salary-reduction measures in September 2020.
- The auditor issued an unqualified opinion on the financial statements. Management assessed disclosure controls and internal control over financial reporting as effective; the auditor did not attest to internal control effectiveness.
Important facts for investors to verify
- Reconcile the reported $1.216 million revenue with test volumes, payer mix, cash collections, and the company’s differing cash-basis versus accrual-basis revenue recognition.
- Track DetermaRx adoption, Medicare collections, commercial payer contracts, clinical-trial progress, and whether COVID-related delays persist.
- Confirm DetermaIO’s clinical evidence, launch timing, regulatory status, and reimbursement path; verify progress and economics for other pipeline tests.
- Assess cash burn and runway against operating plans, debt and lease commitments, contingent consideration, and additional equity needs.
- Review the completed Razor acquisition’s integration, remaining royalty obligations, clinical-trial funding commitments, and dilution; separately confirm whether and on what terms the Chronix merger closed.
- Monitor customer concentration, the PPP forgiveness outcome, and any impairment or regulatory developments affecting acquired assets and test commercialization.